Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
Primary:
To assess the safety of SL77.0499-10 10mg administered once daily for one year in patients
with lower urinary tract symptoms related to BPH.
Secondary:
- To provide the information on the efficacy of SL77.0499-10 10mg administered once daily
for one year in patients with lower urinary tract symptoms related to BPH.
- To document the plasma concentration of SL77.0499-10 after repeated administration of
SL77.0499-10 10mg administered once daily in patients with lower urinary tract symptoms
related to BPH.